Table 1 Characteristics of the included trials in this meta-analysis
From: Lamivudine therapy for chronic hepatitis B in children: a meta-analysis
Author | Year | Geographic Locale | Study Design | Regimen | Sample size | Duration, weeks |
|---|---|---|---|---|---|---|
Jonas | 2002 | North America, South America, and Europe | RCT | 3 mg/kg· d | 286 | 52 |
Figlerowicz | 2005 | Poznan | cohort | 3 mg/kg· d | 152 | 48 |
Zhang | 2011 | China, Henan province | RCT | 3 mg/kg· d | 100 | 24 |
Luo | 2006 | China, Hunan province | RCT | 3 mg/kg· d | 58 | 72 |
Wang | 2014 | China, Hubei province | cohort | 3 mg/kg· d | 80 | 52 |
He | 2007 | China, Sichuan province | RCT | 3 mg/kg· d | 193 | 52 |
Feng | 2011 | China, Shanxi province | RCT | 3 mg/kg· d | 113 | 60 |
Wang | 2012 | China, Jiangxi province | cohort | 3 mg/kg· d | 218 | 208 |
Liu | 2006 | China, Jilin province | cohort | 3 mg/kg· d | 70 | 52 |
Xu | 2004 | China, Guangdong province | RCT | 3 mg/kg· d | 63 | 96 |
Wang | 2013 | China, Jiangxi province | RCT | 3 mg/kg· d | 80 | 72 |
Gao | 2002 | China, Shandong province | RCT | 3 mg/kg· d | 80 | 52 |
Yang | 2010 | China, Jiangxi province | cohort | 3 mg/kg· d | 63 | 48 |